Various biomarkers are available to support the diagnosis of neurodegenerative diseases in
clinical and research settings. Among the molecular imaging biomarkers, amyloid-PET …

Alzheimer's disease is a progressive neurodegenerative disease that typically manifests
clinically as an isolated amnestic deficit that progresses to a characteristic dementia …

Cognitive impairment creates significant challenges for patients, their families and friends,
and clinicians who provide their health care. Early recognition allows for diagnosis and …

Background The existing dementia risk models are limited to known risk factors and
traditional statistical methods. We aimed to employ machine learning (ML) to develop a …

Background Mild cognitive impairment (MCI) due to Alzheimer's disease is the symptomatic
predementia phase of Alzheimer's disease dementia, characterised by cognitive and …

Disease-modifying treatment trials are increasingly advanced to the prodromal or preclinical
phase of Alzheimer's disease (AD), and inclusion criteria are based on biomarkers rather …

Objective Olfactory function is altered in mild cognitive impairment (MCI) and Alzheimer's
disease (AD); therefore, it may serve as a useful tool for the early detection of MCI before its …

Time-dependent data collected in studies of Alzheimer's disease usually has missing and
irregularly sampled data points. For this reason time series methods which assume regular …

We studied whether electroencephalography (EEG)-derived measures of brain oscillatory
activity are related to clinical progression in nondemented, amyloid positive subjects. We …

Subjective cognitive decline (SCD), characterized by a very early and subtle cognitive
decline prior to the appearance of objective cognitive impairment, is considered to be the …